This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Scandion Oncology Resultados de beneficios anteriores

-56.8%

Tasa de crecimiento de los beneficios

-26.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	0.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-60.8%
Margen neto	n/a
Próxima actualización de resultados	25 Aug 2022

No hay actualizaciones

No hay actualizaciones

Cómo gana y gasta dinero Scandion Oncology. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:SCOL BTA Ingresos, gastos y beneficios (DKK Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 22	-56	10	53
31 Dec 21	-52	8	48
30 Sep 21	-43	22	30
30 Jun 21	-31	11	30
31 Mar 21	-22	1	30
31 Dec 20	-17	3	22
30 Sep 20	-11	27	0
30 Jun 20	-14	23	0
31 Mar 20	-14	19	0
31 Dec 19	-12	16	0
30 Sep 19	-17	5	0
30 Jun 19	-12	4	0
31 Mar 19	-10	3	0
31 Dec 18	-8	3	0
30 Sep 18	-4	1	0

Ingresos de calidad: SCOL BTA is currently unprofitable.

Margen de beneficios creciente: SCOL BTA is currently unprofitable.

Tendencia de beneficios: SCOL BTA is unprofitable, and losses have increased over the past 5 years at a rate of 56.8% per year.

Acelerando crecimiento: Unable to compare SCOL BTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: SCOL BTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).

Alta ROE: SCOL BTA has a negative Return on Equity (-60.84%), as it is currently unprofitable.